Access count of this item: 0

Files in This Item:
This article will be available after a certain embargo period.
Please see the "Rights" information in item metadata display about embargo date.
Title: ニボルマブ投与中に心嚢液貯留を来たした転移性腎細胞癌の1例
Other Titles: A Case of Pericardial Effusion Induced by Nivolumab for Metastatic Renal Cell Carcinoma
Authors: 深江, 彰太  KAKEN_name
田中, 亮  KAKEN_name
吉永, 光宏  KAKEN_name
川村, 憲彦  KAKEN_name
中川, 勝弘  KAKEN_name
谷川, 剛  KAKEN_name
蔦原, 宏一  KAKEN_name
高尾, 徹也  KAKEN_name
山口, 誓司  KAKEN_name
Author's alias: Fukae, Shota
Tanaka, Ryo
Yoshinaga, Mitsuhiro
Kawamura, Norihiko
Nakagawa, Masahiro
Tanigawa, Go
Tsutahara, Koichi
Takao, Tetsuya
Yamaguchi, Seiji
Keywords: Nivolumab
Pericardial effusion
Issue Date: 31-Aug-2019
Publisher: 泌尿器科紀要刊行会
Journal title: 泌尿器科紀要 = Acta urologica Japonica
Volume: 65
Issue: 8
Start page: 329
End page: 332
Abstract: A 72-year-old female with left renal cell carcinoma and lymphadenopathy had undergone hand-assisted laparoscopic left nephrectomy and dissection of the lymph node (papillary renal cell carcinoma, type 2, pT3a pN2 M1). She had been treated with adjuvant chemotherapy with sunitinib, temsirolimus and pazopanib. However, the patient was started on nivolumab due to disease progression. After receiving 5 cycles of nivolumab, she was admitted to our emergency room for chest discomfort and appetite loss. Since computed tomographic (CT) scan showed pericardial effusion, we performed pericardiocentesis. Cytological examination of the pericardial effusion demonstrated leukocytes and no malignant cells. CT scan two weeks after cardiocentesis showed no recurrent pericardial effusion. She became stable with nivolumab, but the administration of nivolumab was discontinued and she started receiving axitinib.
Rights: 許諾条件により本文は2020/09/01に公開
DOI: 10.14989/ActaUrolJap_65_8_329
PubMed ID: 31501401
Appears in Collections:Vol.65 No.8

Show full item record

Export to RefWorks

Export Format: 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.